There are 2789 resources available
862MO - Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
Presenter: Loris De Cecco
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
863MO - Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016
Presenter: Michael Kharouta
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
864MO - Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study
Presenter: Paolo Bossi
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
865MO - RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
Presenter: Nandini Menon
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
1670MO - Validation of a new risk-assessment model for prediction of venous thromboembolism in cancer outpatients: The ONKOTEV score
Presenter: Chiara Alessandra Cella
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1443MO - Differences in hematologists’ and palliative care physicians’ recommended indications and opinions on transfusion therapy for patients with hematological malignancy post-anticancer therapy
Presenter: Yukako Hattori
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1671MO - Impact of antibiotic (ATB) exposure prior to immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
LBA62 - Efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy
Presenter: Marie Fallon
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
LBA63 - Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial
Presenter: Kazuhiro Shimomura
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast
LBA64 - Olanzapine, an alternative to dexamethasone for preventing nausea and vomiting induced by cisplatin-based doublet highly emetogenic chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial
Presenter: Zhigang Liu
Session: Mini oral session - Supportive and palliative care
Resources:
Abstract
Slides
Webcast